Cover Image

Population pharmacokinetic study of pemetrexed in chinese primary advanced non-small cell lung carcinoma patients

The purposes of this study were to identify physiological and genetic factors that contributed to variability of pemetrexed (PEM) exposure and to optimize the dosing regimens for Chinese non-small cell lung carcinoma patients. A prospective population pharmacokinetics (PPK) research was performed in...

Full description

Saved in:

Bibliographic Details
Main Authors:	Peng Cao (Author), Wei Guo (Author), Jun Wang (Author), Sanlan Wu (Author), Yifei Huang (Author), Yang Wang (Author), Yani Liu (Author), Yu Zhang (Author)
Format:	Book
Published:	Frontiers Media S.A., 2022-08-01T00:00:00Z.
Subjects:	article
Online Access:	Connect to this object online.
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Baseline differences in metabolic profiles of patients with lung squamous cell carcinoma responding or not responding to treatment with nanoparticle albumin-bound paclitaxel (nab-paclitaxel)
by: Peng Cao, et al.
Published: (2023)

Application of Population Pharmacokinetic Analysis to Characterize CYP2C19 Mediated Metabolic Mechanism of Voriconazole and Support Dose Optimization
by: SiChan Li, et al.
Published: (2022)

Dyslipidemia in coronavirus disease 2019 pneumonia patients
by: Peng Cao, et al.
Published: (2020)

Pemetrexed-Platinum With or Without Bevacizumab for Chinese Chemo-Naive Advanced Lung Adenocarcinoma Patients: A Real-World Study
by: Xin Li, et al.
Published: (2021)

Pharmacokinetics, Safety and Pharmacokinetics/Pharmacodynamics Analysis of Omadacycline in Chinese Healthy Subjects
by: Haijing Yang, et al.
Published: (2022)

Pemetrexed as second-line therapy for advanced non-small-cell lung cancer (NSCLC)
by: Enriqueta Felip, et al.
Published: (2008)

Population Pharmacokinetics and Dosing Regimen Optimization of Latamoxef in Chinese Children
by: Yang Wang, et al.
Published: (2022)

Discovery of Novel Biomarkers of Therapeutic Responses in Han Chinese Pemetrexed-Based Treated Advanced NSCLC Patients
by: Xiaoqing Zhang, et al.
Published: (2019)

Optimal Scheduling of Bevacizumab and Pemetrexed/Cisplatin Dosing in Non‐Small Cell Lung Cancer
by: Benjamin K. Schneider, et al.
Published: (2019)

The efficacy and safety of pemetrexed-based doublet therapy compared to pemetrexed alone for the second-line treatment of advanced non-small-cell lung cancer: an updated meta-analysis
by: Zhong AY, et al.
Published: (2015)

Anti-angiogenic therapy in ovarian cancer: Current understandings and prospects of precision medicine
by: Chao Mei, et al.
Published: (2023)

Pemetrexed as first-line therapy for non-squamous non-small cell lung cancer
by: Serena Ricciardi, et al.
Published: (2009)

Population Pharmacokinetics and Dose Optimization of Ganciclovir in Critically Ill Children
by: SiChan Li, et al.
Published: (2021)

OUR EXPERIENCE WITH PEMETREXED/ CISPLATIN AS FIRST LINE CHEMOTHERAPY IN PATIENTS WITH ADVANCED NON- SQUAMOUS NON- SMALL CELL LUNG CANCER
by: Deyan N. Davidov
Published: (2013)

Pharmacokinetic, Pharmacokinetic/Pharmacodynamic, and Safety Investigations of Lefamulin in Healthy Chinese Subjects
by: Yingying Hu, et al.
Published: (2023)

Pemetrexed-induced eccrine squamous syringometaplasia manifesting as pseudocellulitis (in a patient with non-small cell lung cancer)
by: Adinia Santosa, MD, et al.
Published: (2017)

Genomic features of Chinese small cell lung cancer
by: Jun Liu, et al.
Published: (2022)

Pharmacokinetics and Safety of Doripenem in Healthy Chinese Subjects and Monte Carlo Dosing Simulations
by: Yu Wang, et al.
Published: (2022)

The item network and domain network of burnout in Chinese nurses
by: Lin Wu, et al.
Published: (2021)

Molecular profiling and prognostic biomarkers in chinese non-small cell lung cancer cohort
by: Fangfang Shen, et al.
Published: (2023)

Population pharmacokinetics of adebrelimab - Support of alternative flat dose regimen in extensive‐stage small‐cell lung cancer
by: Peng Chen, et al.
Published: (2024)

Pharmacokinetics and Pharmacodynamics of Colistin Methanesulfonate in Healthy Chinese Subjects after Multi-Dose Regimen
by: Yaxin Fan, et al.
Published: (2022)

Investigation on the Efficiency of Chinese Herbal Injections for Treating Non-small Cell Lung Cancer With Vinorelbine and Cisplatin Based on Multidimensional Bayesian Network Meta-Analysis
by: Mengwei Ni, et al.
Published: (2021)

PHARMACOECONOMIC EVALUATION OF THE MEDICINAL PRODUCTS ERLOTINIB, DOCETAXEL, PEMETREXED AND GEFITINIB IN THE SECOND-LINE TREATMENT OF LOCALLY-ADVANCED OR METASTATIC NON-SMALL-CELL LUNG CANCER
by: A. U. Kulikov
Published: (2015)

Lefamulin dosing optimization using population pharmacokinetic and pharmacokinetic/pharmacodynamic assessment in Chinese patients with community-acquired bacterial pneumonia
by: Xingchen Bian, et al.
Published: (2024)

Tailoring treatment of nonsmall cell lung cancer by tissue type: role of pemetrexed
by: Steven F Powell, et al.
Published: (2009)

Alvopem® (pemetrexed) safety assessment in patients with non-small cell lung cancer or malignant pleural mesothelioma: a post-marketing surveillance
by: Sharareh Seifi, et al.
Published: (2023)

Integrative population pharmacokinetic/pharmacodynamic analysis of nemonoxacin capsule in Chinese patients with community-acquired pneumonia
by: Yuancheng Chen, et al.
Published: (2023)

Population pharmacokinetics of intravenous daptomycin in critically ill patients: implications for selection of dosage regimens
by: Jianhua Wu, et al.
Published: (2024)

Recent progress in targeted therapy for non-small cell lung cancer
by: Yanxia Xiao, et al.
Published: (2023)

A Phase I Comparative Pharmacokinetic and Safety Study of Two Intravenous Formulations of Vinorelbine in Patients With Advanced Non-Small Cell Lung Cancer
by: Guolan Wu, et al.
Published: (2019)

To explore the effect of kaempferol on non-small cell lung cancer based on network pharmacology and molecular docking
by: Junli Zhang, et al.
Published: (2023)

The effects of rabeprazole on metformin pharmacokinetics and pharmacodynamics in Chinese healthy volunteers
by: Guojing Liu, et al.
Published: (2016)

Cost-effectiveness of pemetrexed in combination with cisplatin as first line treatment for patients with advanced non-squamous non-small-cell
by: Jonathan González García, et al.
Published: (2017)

A Multidimensional Bayesian Network Meta-Analysis of Chinese Herbal Injections for Treating Non-small Cell Lung Cancer With Gemcitabine and Cisplatin
by: Mengwei Ni, et al.
Published: (2021)

Recent Research Advances in Small-Molecule Pan-PIM Inhibitors
by: Lei Xu, et al.
Published: (2022)

Pharmacokinetics and safety of mavacamten in healthy Chinese participants with different CYP2C19 phenotypes
by: Xiaojie Wu, et al.
Published: (2024)

Edema of the face and extremities secondary to pemetrexed
by: Thomas Doyle, MS, et al.
Published: (2023)

Genetic Association of Drug Response to Erlotinib in Chinese Advanced Non-small Cell Lung Cancer Patients
by: Cong Wang, et al.
Published: (2018)

Clinical efficacy and safety analysis of aumolertinib in real-world treatment of EGFR-mutated advanced non-small-cell lung cancer
by: Xiaojuan Zhang, et al.
Published: (2024)